Skip to main content

Advertisement

SpringerLink
Log in

Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators

  • Review article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Diabetes mellitus is a worldwide impacting disorder and the ratio through which the number of diabetic patients had increased worldwide, puts medical professionals to serious stress for its effective management. Due to its polygenic origin and involvement of multiple genes to its pathophysiology, leads to understanding of this ailment more complex. It seems that current interventions, such as dietary changes, life style changes and drug therapy such as oral hypoglycaemics and insulin, are unable to halt the trend. There are various novel and emerging targets on which the researchers are paying attention to combat with this ailment successfully. Human glucokinase (GK) enzyme is one of these novel and emerging targets for management of diabetes. Its availability in the pancreas and liver cells makes this target more lucrative. GK’s presence in the pancreatic and hepatic cells plays a very important function for the management of glucose homoeostasis. Small molecules that activate GK allosterically provide an alternative strategy for restoring/improving glycaemic regulation, especially in type 2 diabetic patients. Although after enduring many setbacks in the development of the GK activators, interest has been renewed especially due to introduction of novel dual acting GK activator dorzagliatin, and a novel hepato-selective GK activator, TTP399. This review article has been formulated to discuss importance of GK in glucose homeostasis, recent updates on small molecules of GK activators, clinical status of GK activators and challenges in development of GK activators.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795.

  2. Grewal AS, Beniwal M, Pandita D, Sekhon BS, Lather V. Recent updates on peroxisome proliferator-activated receptor δ agonists for the treatment of metabolic syndrome. Med Chem. 2016;12:3–21.

    Article  CAS  PubMed  Google Scholar 

  3. Grewal AS, Sekhon BS, Lather V. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus. Mini Rev Med Chem. 2014;14(7):585–602.

    Article  CAS  PubMed  Google Scholar 

  4. Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, Song X, Ren T, Shan P. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10:14790.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Alhadramy MS. Diabetes and oral therapies: a review of oral therapies for diabetes mellitus. J Taibah Univ Med Sci. 2016;11(4):317–29.

    Google Scholar 

  6. Pal M. Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discov Today. 2009;14(15–16):784–92.

    Article  CAS  PubMed  Google Scholar 

  7. Rochester CD, Akiyode O. Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient. World J Diabetes. 2014;5(3):305–15.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Del Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7(17):354–95.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Belay E, Abera A, Mehari A, Gebremeskel G, Endrias A, Endriset K. Achievements of diabetes goals and their determinants in type 2 diabetic patients attending outpatient diabetic clinic in northern Ethiopia. Int J Chronic Dis. 2017;2017:5713187.

    PubMed  PubMed Central  Google Scholar 

  10. Verma AK, Goyal Y, Bhatt D, Dev K, Alsahli MA, Rahmani AH, Almatroudi A. A compendium of perspectives on diabetes: a challenge for sustainable health in the modern era. Diabetes Metab Syndr Obes. 2021;2021(14):2775–87.

    Article  Google Scholar 

  11. Sharma P, Singh S, Thakur V, Sharma N, Grewal AS. Novel and emerging therapeutic drug targets for management of type 2 diabetes mellitus. Obes Med. 2021;23:100329.

    Article  Google Scholar 

  12. Matschinsky F. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes. 1990;39(6):647–52.

    Article  CAS  PubMed  Google Scholar 

  13. Matschinsky F, Porte D. Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000 Med Rep. 2010;2:43.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Meglasson MD, Matschinsky F. Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab Rev. 1986;2(3–4):163–214.

    Article  CAS  PubMed  Google Scholar 

  15. Matschinsky F, Liang Y, Kesavan P, Wang L, Froguel P, Velho G, Cohen D, Permutt MA, Tanizawa Y, Jetton TL, Niswender K, Magnuson MA. Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Invest. 1993;92(5):2092–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Iynedjian PB. Molecular physiology of mammalian glucokinase. Cell Mol Life Sci. 2009;66(1):27–42.

    Article  CAS  PubMed  Google Scholar 

  17. Li W, Zhang X, Sun Y, Liu Z. Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2. Pharmazie. 2020;75(6):230–5.

    CAS  PubMed  Google Scholar 

  18. Agius L. Lessons from glucokinase activators: the problem of declining efficacy. Expert Opin Ther Pat. 2014;24(11):1155–9.

    Article  CAS  PubMed  Google Scholar 

  19. Nakamura A, Terauchi Y. Present status of clinical deployment of glucokinase activators. J Diabetes Investig. 2015;6(2):124–32.

    Article  CAS  PubMed  Google Scholar 

  20. Agius L. Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes. 2008;58(1):18–20.

    Article  CAS  Google Scholar 

  21. Van Schaftingen E, Vandercammen A, Detheux M, Davies DR. The regulatory protein of liver glucokinase. Adv Enzym Regul. 1992;32:133–48.

    Article  Google Scholar 

  22. Van Schaftingen E. Short-term regulation of glucokinase. Diabetologia. 1994;37:S43–7.

    Article  PubMed  Google Scholar 

  23. Baltrusch S, Francini F, Lenzen S, Tiedge M. Interaction of glucokinase with the liver regulatory protein is conferred by leucine-asparagine motifs of the enzyme. Diabetes. 2005;54(10):2829–37.

    Article  CAS  PubMed  Google Scholar 

  24. Agius L. Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes. 2009;58(1):18–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gomis RR, Favre C, García-Rocha M, Fernández-Novell JM, Ferrer JC, Guinovart JJ. Glucose 6-phosphate produced by gluconeogenesis and by glucokinase is equally effective in activating hepatic glycogen synthase. J Biol Chem. 2003;278(11):9740–6.

    Article  CAS  PubMed  Google Scholar 

  26. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanné-Chantelot C, Ellard S, Gloyn AL. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009;30(11):1512–26.

    Article  CAS  PubMed  Google Scholar 

  27. Rines AK, Sharabi K, Tavares CD, Puigserver P. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat Rev Drug Discov. 2016;15(11):786–804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. Exp Mol Med. 2016;48(3):e219.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Perseghin G. Exploring the in vivo mechanisms of action of glucokinase activators in type 2 diabetes. J Clin Endocrinol Metab. 2010;95:4871–3.

    Article  CAS  PubMed  Google Scholar 

  30. Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017;13(10):572–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Choi JM, Seo MH, Kyeong HH, Kim E, Kim HS. Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase. Proc Natl Acad Sci U S A. 2013;110(25):10171–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Raimondo A, Rees MG, Gloyn AL. Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism. Curr Opin Lipidol. 2015;26(2):88–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Matschinsky F, Wilson DF. The central role of glucokinase in glucose homeostasis: a perspective 50 years after demonstrating the presence of the enzyme in islets of langerhans. Front Physiol. 2019;10:148.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Toulis KA, Nirantharakumar K, Pourzitaki C, Barnett AH, Tahrani AA. Glucokinase activators for type 2 diabetes: challenges and future developments. Drugs. 2020;80:467–75.

    Article  CAS  PubMed  Google Scholar 

  35. Walker DG, Rao S. The role of glucokinase in the phosphorylation of glucose by rat liver. Biochem J. 1964;90(2):360–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Al-Hasani H, Tschöp MH, Cushman SW. Two birds with one stone: novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism. Mol Interv. 2003;3(7):367–70.

    Article  CAS  PubMed  Google Scholar 

  37. Grewal AS, Lather V, Charaya N, Sharma N, Singh S, Kairys V. Recent developments in medicinal chemistry of allosteric activators of human glucokinase for type 2 diabetes mellitus therapeutics. Curr Pharm Des. 2020;26(21):2510–52.

    Article  CAS  PubMed  Google Scholar 

  38. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky F, Grippo JF. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003;301(5631):370–3.

    Article  CAS  PubMed  Google Scholar 

  39. Behera P, Behera D, Satpati S, Agnihotri G, Nayak S, Padhi P, Dixit A. Molecular modeling and identification of novel glucokinase activators through stepwise virtual screening. J Mol Graph Model. 2015;57:122–30.

    Article  CAS  PubMed  Google Scholar 

  40. Park K, Lee BM, Hyun KH, Han T, Lee DH, Choi HH. Design and synthesis of acetylenyl benzamide derivatives as novel glucokinase activators for the treatment of T2DM. ACS Med Chem Lett. 2015;6:296–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Paczal A, Bálint B, Wéber C, Szabó ZB, Ondi L, Theret I, De Ceuninck F, Bernard C, Ktorza A, Perron-Sierra F, Kotschy A. Structure-activity relationship of azaindole-based glucokinase activators. J Med Chem. 2016;59:687–706.

    Article  CAS  PubMed  Google Scholar 

  42. Cheruvallath Z, Gwaltney SL, Sabat M, Tang M, Wang H, Jennings A, Hosfield D, Lee B, Wu Y, Halkowycz P, Grimshaw CE. Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators. Bioorg Med Chem Lett. 2017;27(12):2678–82.

    Article  CAS  PubMed  Google Scholar 

  43. Zhang L, Hu S, Lei L, Zhang Y, Zhang L, Song H, Shen Z, Feng Z. Design, synthesis and evaluation of novel derivatives of orotic acid amide as potent glucokinase activators. Lett Drug Des Discov. 2017;14(3):252–61.

    Article  CAS  Google Scholar 

  44. Singh R, Lather V, Pandita D, Judge V, Arumugam KN, Grewal AS. Synthesis, docking and antidiabetic activity of some newer benzamide derivatives as potential glucokinase activators. Lett Drug Des Discov. 2017;14(5):540–53.

    Article  CAS  Google Scholar 

  45. Charaya N, Pandita D, Grewal AS, Lather V. Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators. Comput Biol Chem. 2018;73:221–9.

    Article  CAS  PubMed  Google Scholar 

  46. Bano S, Khan AU, Asghar F, Usman M, Badshah A, Ali S. Computational and pharmacological evaluation of ferrocene-based acyl ureas and homoleptic cadmium carboxylate derivatives for anti-diabetic potential. Front Pharmacol. 2018;8:1001.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Grewal AS, Kharb R, Prasad DN, Dua JS, Lather V. N-pyridin-2-yl benzamide analogues as allosteric activators of glucokinase: design, synthesis, in vitro, in silico and in vivo evaluation. Chem Biol Drug Des. 2019;93(3):364–72.

    Article  CAS  PubMed  Google Scholar 

  48. Grewal AS, Kharb R, Prasad DN, Dua JS, Lather V. Design, synthesis and evaluation of novel 3,5-disubstituted benzamide derivatives as allosteric glucokinase activators. BMC Chem. 2019;13(1):2.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Singh S, Arora S, Dhalio E, Sharma S, Arora K, Grewal AS. Design and synthesis of newer N-benzimidazol-2yl benzamide analogues as allosteric activators of human glucokinase. Med Chem Res. 2021;30:760–70.

    Article  CAS  Google Scholar 

  50. Arora S, Grewal AS, Sharma N, Arora K, Dhalio E, Singh S. Design, synthesis, and evaluation of some novel N-benzothiazol-2-yl benzamide derivatives as allosteric activators of human glucokinase. J Appl Pharm Sci. 2021;11(Suppl 1):038–47.

    CAS  Google Scholar 

  51. Filipski KJ, Pfefferkorn JA. A patent review of glucokinase activators and disruptors of the glucokinase–glucokinase regulatory protein interaction: 2011–2014. Expert Opin Ther Pat. 2014;24(8):875–91.

    Article  CAS  PubMed  Google Scholar 

  52. Sarabu R, Berthel SJ, Kester RF, Tilley JW. Novel glucokinase activators: a patent review (2008–2010). Expert Opin Ther Pat. 2011;21(1):13–33.

    Article  CAS  PubMed  Google Scholar 

  53. Pfeferkorn JA. Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. Expert Opin Drug Discov. 2013;8(3):319–30.

    Article  CAS  Google Scholar 

  54. Egan A, Vella A. TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes. Expert Opin Investig Drugs. 2019;28(9):741–7.

    Article  CAS  PubMed  Google Scholar 

  55. Dransfield PJ, Pattaropong V, Lai S, Fu Z, Kohn TJ, Du X, Cheng A, Xiong Y, Komorowski R, Jin L, Conn M, Tien E, DeWolf WE Jr, Hinklin RJ, Aicher TD, Kraser CF, Boyd SA, Voegtli WC, Condroski KR, et al. Novel series of potent glucokinase activators leading to the discovery of AM-2394. ACS Med Chem Lett. 2016;7(7):714–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Efanov AM, Barrett DG, Brenner MB, Briggs SL, Delaunois A, Durbin JD, Giese U, Guo H, Radloff M, Gil GS, Sewing S, Wang Y, Weichert A, Zaliani A, Gromada J. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology. 2005;146:3696–701.

    Article  CAS  PubMed  Google Scholar 

  57. Doliba NM, Fenner D, Zelent B, Bass J, Sarabu R, Matschinsky F. Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activation. Diabetes Obes Metab. 2012;14(Suppl 3):109–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Mahmoodi M, Zarei S, Rezaeian M, Arababadi MK, Ghasemi H, Khoramdelazad H, Rezayati N, Hasanshahi G, Hosseini-Zijoud S-M. Persian shallot (Allium hirtifolium Boiss) extract elevates glucokinase (GCK) activity and gene expression in diabetic rats. Am J Plant Sci. 2013;4(7):1393–9.

    Article  CAS  Google Scholar 

  59. Ighodaro OM, Akinloye OA, Ugbaja RN, Omotainse SO. Sapium ellipticum (Hochst) Pax ethanol leaf extract modulates glucokinase and glucose-6-phosphatase activities in streptozotocin induced diabetic rats. Asian Pac J Trop Biomed. 2017;7(6):544–8.

    Article  Google Scholar 

  60. Angadi K, Gundampati R, Jagannadham M, Kandru A. Molecular docking studies of guggultetrol from Nymphaea pubescens with target glucokinase (GK) related to type-II diabetes. J Appl Pharm Sci. 2012;3(2):127–31.

    Google Scholar 

  61. Hikino H, Ishiyama M, Suzuki Y, Konno C. Mechanisms of hypoglycemic activity of ganoderan B: a glycan of Ganoderma lucidum fruit bodies. Planta Med. 1989;55(5):423–8.

    Article  CAS  PubMed  Google Scholar 

  62. Kang YJ, Jung UJ, Lee MK, Kim HJ, Jeon SM, Park YB, Chung HG, Baek NI, Lee KT, Jeong TS, Choi MS. Eupatilin, isolated from Artemisia princeps Pampanini, enhances hepatic glucose metabolism and pancreatic beta-cell function in type 2 diabetic mice. Diabetes Res Clin Pract. 2008;82(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  63. Qian-Cutrone J, Ueki T, Huang S, Mookhtiar KA, Ezekiel R, Kalinowski SS, Brown KS, Golik J, Lowe S, Pirnik DM, Hugill R, Veitch JA, Klohr SE, Whitney JL, Manly SP. Glucolipsin a and B, two new glucokinase activators produced by Streptomyces purpurogeniscleroticus and Nocardia vaccinii. J Antibiot. 1999;52(3):245–55.

    Article  CAS  Google Scholar 

  64. Grewal AS, Sharma N, Singh S, Arora S. Molecular docking studies of phenolic compounds from Syzygium cumini with multiple targets of type 2 diabetes. J Pharm Technol Res Manag. 2018;6(2):125–33.

    Article  Google Scholar 

  65. Singh AB, Singh N, Akanksha J, Maurya R, Srivastava AK. Coagulanolide modulates hepatic glucose metabolism in C57BL/KsJ-db/db mice. Hum Exp Toxicol. 2012;31(10):1056–65.

    Article  CAS  PubMed  Google Scholar 

  66. Min Q, Cai X, Sun W, Gao F, Li Z, Zhang Q, Wan LS, Li H, Chen J. Identification of mangiferin as a potential glucokinase activator by structure-based virtual ligand screening. Sci Rep. 2017;7:44681.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Jeyabaskar S, Viswanathan T, Mahendran R, Nishandhini M. In silico molecular docking studies to investigate interactions of natural camptothecin molecule with diabetic enzymes. Res J Pharm Technol. 2017;10(9):2917–22.

    Article  Google Scholar 

  68. Grewal AS, Sharma N, Singh S. Molecular docking investigation of compounds from Sapium ellipticum (Hochst) Pax as allosteric activators of human glucokinase. Int J Pharm Qual Assur. 2019;10(4):588–96.

    Article  Google Scholar 

  69. Scheen AJ. Investigational insulin secretagogues for type 2 diabetes. Expert Opin Investig Drugs. 2016;25(4):405–22.

    Article  CAS  PubMed  Google Scholar 

  70. Kamimura H, Ito S, Chijiwa H, Okuzono T, Ishiguro T, Yamamoto Y, Nishinoaki S, Ninomiya SI, Mitsui M, Kalgutkar AS, Yamazaki H, Suemizu H. Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. Xenobiotica. 2017;47(5):382–93.

    Article  CAS  PubMed  Google Scholar 

  71. Tsumura Y, Tsushima Y, Tamura A, Hasebe M, Kanou M, Kato H Kobayashi T. TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models. PLoS One 2017;12(2):e0172252.

  72. Zhu XX, Zhu DL, Li XY, Li YL, Jin XW, Hu TX, Zhao Y, Li YG, Zhao GY, Ren S, Zhang Y, Ding YH, Chen L. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: a 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab. 2018;20(9):2113–20.

    Article  CAS  PubMed  Google Scholar 

  73. Vella A, Freeman JL, Dunn I, Keller K, Buse JB, Valcarce C. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Sci Transl Med. 2019;11:475.

    Article  CAS  Google Scholar 

  74. Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, Zhi J, Grippo JF, Balena R. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab. 2010;95(11):5028–36.

    Article  CAS  PubMed  Google Scholar 

  75. Waring MJ, Clarke DS, Fenwick MD, Godfrey L, Groombridge SD, Johnstone J, McKerrecher D, Pike KG, Rayner JW, Robb GR, Wilson I. Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656. Med Chem Commun. 2012;3:1077–81.

    Article  CAS  Google Scholar 

  76. Denney WS, Denham DS, Riggs MR, Amin NB. Glycemic effect and safety of a systemic, partial glucokinase activator, PF-04937319, in patients with type 2 diabetes mellitus inadequately controlled on metformin-a randomized, crossover, active-controlled study. Clin Pharmacol Drug Dev. 2016;5(6):517–27.

    Article  CAS  PubMed  Google Scholar 

  77. Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H, Davies MJ, Kaufman KD, Goldstein BJ. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011;34(12):2560–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Hinklin RJ, Baer BR, Boyd SA, Chicarelli MD, Condroski KR, DeWolf WE Jr, Fischer J, Frank M, Hingorani GP, Lee PA, Neitzel NA, Pratt SA, Singh A, Sullivan FX, Turner T, Voegtli WC, Wallace EM, Williams L, Aicher TD. Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator. Bioorg Med Chem. 2020;28(1):115232.

    Article  CAS  PubMed  Google Scholar 

  79. Zhang X, Schneck K, Bue-Valleskey J, Yeo KP, Heathman M, Sinha V. Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator. J Pharmacokinet Pharmacodyn. 2013;40(1):53–65.

    Article  CAS  PubMed  Google Scholar 

  80. Scheen AJ. New hope for glucokinase activators in type 2 diabetes? Lancet Diabetes Endocrinol. 2018;6(8):591–3.

    Article  PubMed  Google Scholar 

  81. Zheng S, Shao F, Ding Y, Fu Z, Fu Q, Ding S, Xie L, Chen J, Zhou S, Zhang H, Zhou H, Chen Y, Sun C, Zhu J, Zheng X, Yang T. Safety, pharmacokinetics, and pharmacodynamics of globalagliatin, a glucokinase activator, in Chinese patients with type 2 diabetes mellitus: a randomized, phase Ib, 28-day ascending dose study. Clin Drug Investig. 2020;40(12):1155–66.

    Article  CAS  PubMed  Google Scholar 

  82. Matschinsky F. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci. 2013;34(2):90–9.

    Article  CAS  PubMed  Google Scholar 

  83. Brouwers M, Jacobs C, Bast A, Stehouwer CDA, Schaper NC. Modulation of glucokinase regulatory protein: a double-edged sword? Trends Mol Med. 2015;21(10):583–94.

    Article  CAS  PubMed  Google Scholar 

  84. Tornovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben Haroush R, Hija A, Stolovich-Rain M, Furth-Lavi J, Granot Z, Porat S, Philipson LH, Herold KC, Bhatti TR, Stanley C, Ashcroft FM, In't Veld P, Saada A, Magnuson MA, et al. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in beta cells. Cell Metab. 2014;19(1):109–21.

    Article  CAS  PubMed  Google Scholar 

  85. Gao Q, Zhang W, Li T, Yang G, Zhu W, Chen N, Jin H. The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus: a protocol for systematic review and meta-analysis. Medicine. 2021;100(7):e24873.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India

    Prateek Sharma, Sukhbir Singh & Neelam Sharma

  2. Government Pharmacy College, Nagrota Bhagwan, Kangra, Himachal Pradesh, India

    Prateek Sharma

  3. Guru Gobind Singh College of Pharmacy, Yamuna Nagar, Haryana, India

    Deepak Singla, Kumar Guarve & Ajmer Singh Grewal

Authors
  1. Prateek Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sukhbir Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neelam Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Deepak Singla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kumar Guarve
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ajmer Singh Grewal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ajmer Singh Grewal.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, P., Singh, S., Sharma, N. et al. Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators. J Diabetes Metab Disord 21, 1129–1137 (2022). https://doi.org/10.1007/s40200-022-01019-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-022-01019-x

Keywords

Search

Navigation